WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

IKT past revenue growth

How has IKT's revenue growth performed historically?
Company
111.03%
Industry
148.4%
Market
16.96%
IKT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IKT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IKT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IKT earnings and revenue history

Current Revenue
$260.5k
Current Earnings
-$19.0M
Current Profit Margin
-7,304.7%

IKT Return on Equity

Current Company
-107.5%
Current Industry
-63.5%
Current Market
188%
IKT's Return on Equity (-107.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when IKT announces earnings.

IKT Return on Assets

Current Company
-91.8%
Current Industry
2.9%
IKT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IKT Return on Capital Employed

Current Company
-171.93%
Current Industry
19.5%
IKT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

IKT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IKT$260.50k-$18.85M-$19.03M-42.21%N/A
IMNN$0.00-$19.88M-$19.51M-100.00%N/A
COEP$0.00-$20.16M-$21.27M-100.00%N/A
MNPR$0.00-$8.40M-$8.40MN/AN/A
SNTI$2.56M-$65.63M-$71.06M+152.19%N/A
View Top Biotech Stocks

IKT earnings dates

Next earnings date
May 13, 2024

Inhibikase Therapeutics Earnings & Revenue FAQ

What were IKT's earnings last quarter?

On Invalid Date, Inhibikase Therapeutics (NASDAQ: IKT) reported Q4 2023 earnings per share (EPS) of -$0.64, up 37.25% year over year. Total Inhibikase Therapeutics earnings for the quarter were -$4.18 million. In the same quarter last year, Inhibikase Therapeutics's earnings per share (EPS) was -$1.02.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.

What was IKT's earnings growth in the past year?

As of Q2 2024, Inhibikase Therapeutics's earnings has grown year over year. Inhibikase Therapeutics's earnings in the past year totalled -$19.03 million.

What is IKT's earnings date?

Inhibikase Therapeutics's earnings date is Invalid Date. Add IKT to your watchlist to be reminded of IKT's next earnings announcement.

What was IKT's revenue last quarter?

On Invalid Date, Inhibikase Therapeutics (NASDAQ: IKT) reported Q4 2023 revenue of $1.00 up 100% year over year. In the same quarter last year, Inhibikase Therapeutics's revenue was $63.57 thousand.

What was IKT's revenue growth in the past year?

As of Q2 2024, Inhibikase Therapeutics's revenue has grown 111.03% year over year. This is 37.37 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Inhibikase Therapeutics's revenue in the past year totalled $260.50 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.